Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
SW Choi, T Braun, I Henig, E Gatza… - Blood, The Journal …, 2017 - ashpublications.org
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
[HTML][HTML] Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - Blood, 2017 - Elsevier
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - Blood, 2017 - cir.nii.ac.jp
抄録< jats: title> Key Points</jats: title>< jats: p> Grade 2 to 4 acute GVHD in URD HCT
patients who received vorinostat and tacrolimus/methotrexate after myeloablative …
patients who received vorinostat and tacrolimus/methotrexate after myeloablative …
[引用][C] Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - 2017 - repository.ubn.ru.nl
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
[HTML][HTML] Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - Blood, 2017 - ncbi.nlm.nih.gov
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - …, 2017 - pubmed.ncbi.nlm.nih.gov
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - Blood, 2017 - europepmc.org
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
SW Choi, T Braun, I Henig, E Gatza, J Magenau… - Blood, 2017 - europepmc.org
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …